The company's topical manufacturing facility at Ahmedabad has received
an EIR from the United States Food and Drug Administration (USFDA)
signifying the successful closure of the audit, Cadila Healthcare said
in a filing to the BSE. The facility completed the USFDA audit from
December 16 to 20, 2019 with zero 483 observations, it added.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cadila-healthcare-gets-eir-from-usfda-for-its-ahmedabad-facility/articleshow/74063106.cms
No comments:
Post a Comment